Selgantolimod (GS-9688)

About Gilead

Gilead Sciences is a fully integrated biopharmaceutical giant with a mission to create a healthier world by advancing transformative therapies for serious diseases. It achieved historic success by pioneering curative treatments for hepatitis C and life-sustaining regimens for HIV, establishing a dominant virology franchise. The company's current strategy is to expand its leadership into oncology and inflammation through internal R&D and strategic acquisitions, while maintaining its commitment to health equity and global access.

About Gilead Sciences

Gilead Sciences is a research-based biopharmaceutical company with a mission to advance the care of patients suffering from life-threatening diseases worldwide. Founded in 1987, the company has achieved historic success by transforming HIV and hepatitis C into manageable or curable conditions and has strategically expanded into oncology through its cell therapy subsidiary, Kite Pharma, and into inflammatory diseases. Its strategy is anchored in three core therapeutic pillars—Virology, Oncology, and Inflammation—supported by a $5.9B annual R&D investment and a goal to deliver 10+ transformative therapies by 2030. As a publicly traded entity (NASDAQ: GILD) with a market cap of ~$169B, Gilead leverages its scientific expertise, global scale, and community partnerships to sustain its leadership position.

Therapeutic Areas

Other Chronic Hepatitis B Drugs